William Blair Reaffirms “Outperform” Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

William Blair reiterated their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note published on Friday,RTT News reports.

ALNY has been the topic of a number of other reports. StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. HC Wainwright upped their price target on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research report on Monday, February 24th. Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research note on Friday. Royal Bank of Canada reissued an “outperform” rating and issued a $310.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Finally, JPMorgan Chase & Co. boosted their price objective on Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $310.22.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $283.34 on Friday. The stock has a market cap of $36.68 billion, a PE ratio of -130.57 and a beta of 0.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The stock’s 50 day simple moving average is $257.16 and its 200-day simple moving average is $259.65.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Sell-side analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently modified their holdings of ALNY. OneDigital Investment Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth about $281,000. Natixis Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth about $2,751,000. Mutual of America Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 26.7% in the third quarter. Mutual of America Capital Management LLC now owns 1,924 shares of the biopharmaceutical company’s stock worth $529,000 after acquiring an additional 405 shares in the last quarter. Pathstone Holdings LLC increased its holdings in shares of Alnylam Pharmaceuticals by 11.2% in the third quarter. Pathstone Holdings LLC now owns 6,249 shares of the biopharmaceutical company’s stock worth $1,719,000 after acquiring an additional 629 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth about $902,000. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.